(NASDAQ: CGON) Cg Oncology's forecast annual revenue growth rate of 341.55% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 34.54%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.57%.
Cg Oncology's revenue in 2026 is $5,071,000.On average, 15 Wall Street analysts forecast CGON's revenue for 2026 to be $328,995,224, with the lowest CGON revenue forecast at $86,438,424, and the highest CGON revenue forecast at $1,690,223,990. On average, 15 Wall Street analysts forecast CGON's revenue for 2027 to be $8,600,093,927, with the lowest CGON revenue forecast at $3,457,536,942, and the highest CGON revenue forecast at $14,866,526,824.
In 2028, CGON is forecast to generate $43,497,931,585 in revenue, with the lowest revenue forecast at $18,420,204,461 and the highest revenue forecast at $66,958,907,378.